Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Growth | Market Cap | Revenue | EBITDA | Earnings | EPS | Rev. Y/Y | Rev. 5Y | Earn. Y/Y | Earn. 5Y | Earnings Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TGTX | TG THERAPEUTICS INC | $7.15B | $329.00M | $49.69M | $23.38M | $0.16 | 40.80% | 364.59% | 77.78% | N/A | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.13B | $235.13M | $31.73M | $5.75M | $0.04 | 33.97% | 274.78% | N/A | N/A | |||
| CORT | CORCEPT THERAPEUTICS INC | $7.58B | $675.04M | $136.81M | $139.73M | $1.35 | 39.94% | 17.11% | 32.35% | 10.49% | |||
| KRYS | KRYSTAL BIOTECH INC | $4.89B | $290.52M | $102.07M | $89.16M | $3.12 | 473.02% | N/A | 680.00% | N/A | 2025-05-05 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $610.34M | $99.60M | $10.34M | $8.55M | $0.11 | 19.18% | 16.56% | N/A | N/A | 2025-05-06 | ||
| SPRY | ARS PHARMACEUTICALS INC | $1.37B | $89.15M | $8.37M | $8.00M | $0.08 | 297,063.33% | N/A | N/A | N/A | 2025-05-07 | ||
| GYRE | GYRE THERAPEUTICS INC | $913.66M | $105.76M | $19.63M | $12.09M | $0.14 | -6.78% | N/A | N/A | N/A | 2025-06-12 | ||
| ARGX | ARGENX SE | $39.20B | $4.73M | $114.32M | $905.48M | $15.13 | -88.53% | -44.77% | N/A | N/A | 2025-05-07 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.95B | $491.73M | $254.32M | $163.89M | $1.38 | 23.49% | 36.89% | 105.97% | 34.80% | 2025-05-06 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.69B | $714.73M | $233.41M | $145.49M | $2.56 | 22.80% | 160.18% | 17.97% | N/A | |||
| VCEL | VERICEL CORP | $1.90B | $237.22M | $23.28M | $10.36M | $0.21 | 20.10% | 15.02% | N/A | N/A | 2025-05-06 | ||
| EXEL | EXELIXIS INC | $10.96B | $2.17B | $737.90M | $521.27M | $1.80 | 18.49% | 17.51% | 176.92% | 11.17% | |||
| SRPT | SAREPTA THERAPEUTICS INC | $6.05B | $1.90B | $314.67M | $235.24M | $2.47 | 52.97% | 37.94% | N/A | N/A | |||
| HALO | HALOZYME THERAPEUTICS INC | $7.56B | $1.02B | $656.54M | $444.09M | $3.50 | 22.44% | 38.95% | 64.32% | N/A | 2025-05-05 | ||
| RIGL | RIGEL PHARMACEUTICALS INC | $349.40M | $179.28M | $28.51M | $17.49M | $0.99 | 53.38% | 24.77% | N/A | N/A | 2025-05-05 | ||
| RPRX | ROYALTY PHARMA PLC | $18.92B | $2.26B | $1.08B | $858.98M | $1.92 | -3.86% | 4.52% | -24.41% | N/A | 2025-05-07 | ||
| NVO | NOVO NORDISK A S | $296.70B | $40.56B | $20.43B | $14.10B | $3.17 | 17.71% | 17.33% | 14.32% | 20.88% | |||
| MDXG | MIMEDX GROUP INC | $1.01B | $348.88M | $66.07M | $42.42M | $0.29 | 8.52% | 3.12% | -27.50% | N/A | |||
| ADMA | ADMA BIOLOGICS INC | $5.66B | $426.45M | $147.69M | $197.67M | $0.85 | 65.15% | 70.79% | N/A | N/A | 2025-05-07 | ||
| INCY | INCYTE CORP | $12.13B | $4.41B | $406.83M | $21.27M | $0.29 | 17.13% | 14.63% | -91.29% | N/A | |||
| MNKD | MANNKIND CORP | $1.53B | $285.50M | $77.54M | $27.59M | $0.10 | 43.50% | 35.27% | N/A | N/A | 2025-05-06 | ||
| VCYT | VERACYTE INC | $2.38B | $445.76M | $54.16M | $24.14M | $0.32 | 23.46% | 29.93% | N/A | N/A | 2025-05-05 | ||
| GNFT | GENFIT SA | $204.73M | $80.61M | $9.48M | $1.71M | $0.03 | 74.21% | 9.93% | N/A | N/A | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $7.10B | $4.07B | $1.37B | $560.12M | $9.06 | 6.12% | 13.48% | 38.32% | -0.35% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $12.15B | $2.85B | $650.86M | $426.86M | $2.25 | 17.97% | 10.86% | 152.81% | N/A | |||
| TECH | BIO-TECHNE CORP | $7.96B | $1.20B | $312.12M | $158.14M | $1.00 | 4.46% | 9.94% | -29.08% | -4.82% | |||
| ACAD | ACADIA PHARMACEUTICALS INC | $2.44B | $957.80M | $273.96M | $226.45M | $1.37 | 31.85% | 23.08% | N/A | N/A | 2025-05-06 | ||
| GMAB | GENMAB A | $14.00B | $3.01B | $1.61B | $1.10B | $1.71 | 23.01% | 30.25% | 72.64% | 27.14% | |||
| UTHR | UNITED THERAPEUTICS CORP | $13.67B | $2.99B | $1.68B | $1.21B | $27.08 | 19.85% | 15.73% | 21.11% | 17.60% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $64.65B | $14.09B | $5.53B | $4.50B | $41.77 | 7.52% | 14.97% | 15.64% | 14.92% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.